Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

‍

• Berlin-based company Cantourage shortlisted for the 11th European Small and Mid-Cap Awards 2023
• Cantourage nominated for "Star of Innovation" category; this recognizes companies that put innovation at the core of their strategy
• Winners of the competition will be announced on November 14, 2023 in Bilbao, Spain

‍

Berlin, September 25, 2023 – Cantourage Group SE (hereinafter "Cantourage", ISIN: DE000A3DSV01, www.cantourage.com), a leading European producer and distributor of medical cannabis, has made it onto the shortlist and thus into the narrowest group of candidates for the 11th European Small and Mid-Cap Awards 2023. The awards were introduced by the European Commission in 2013 and recognize listed European companies in four different categories. Co-organizers are EuropeanIssuers, a European association of listed companies, and the Federation of European Securities Exchanges (FESE).

‍

Cantourage was nominated for the "Star of Innovation" category. This category includes companies that place innovation at the core of their corporate development strategy. Other criteria in this category are good corporate governance and the sector-specific success of the company. In addition, special attention is paid to the specific future potential of the company's innovation.

‍

The winners of the competition will be announced at the awards ceremony on November 14, 2023 in Bilbao, Spain. The shortlist and winners in each category will be determined by an independent jury. It is compiled by the European Commission and is made up of journalists and representatives of the financial industry. According to the organizers, the aim of the awards is to highlight the best small and medium-sized companies in Europe that have gained access to the capital markets through an IPO. This should encourage smaller companies in Europe in particular to consider a stock exchange listing.

‍

Philip Schetter, CEO of Cantourage, comments "We are delighted to be shortlisted for the European Small and Mid-Cap Awards. As a leading publicly traded European medical cannabis company, Cantourage has always grown dynamically. Innovations such as our dronabinol solution or our "Fast Track Access" platform played a decisive role in this. To maintain our profitable growth course in the future, we are continuously working on further innovations. Recently, we reached another milestone with the launch of our own online platform for cannabis on prescription called Telecan°. Being shortlisted in the 'Star of Innovation' category is a source of pride for us and a great endorsement of our performance since going public in November 2022."

‍

About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.

More information: www.cantourage.com

‍

This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.

In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.

Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.

‍

Press contacts
Klaas Geller | klaas.geller@tonka-pr.com | +49.17674717519
Pia Senkel | pia.senkel@tonka-pr.com | +49.1733702649